The new anti-cancer drug BGB-15025 tablets has successfully passed the review in China, and this new drug has not only been clinically tested in China, but also passed the approval of the US Food and Drug Administration, bringing anti-cancer gospel to the best cancer patients in the two countries
BGB-15025 is an investigational small molecule inhibitor of HPK1, a key negative feedback regulator of T cell receptor signaling. Preclinical studies have shown that inhibition of HPK1 enhances T cell activation. In addition, preclinical studies have shown that BGB-15025 in combination with tislelizumab has anti-tumor activity and has a broad window.
The famous tertiary hospitals in China, West China Hospital of Sichuan University, Henan Provincial Cancer Hospital, Tianjin Cancer Hospital, and Shanghai Pulmonary Hospital have opened the window for Chinese patients
This clinical trial is really rare, patients who are not effective in fighting cancer can enter the clinic as soon as possible, and continue their lives through clinical practice, and they can **good news of new drugs**, and save people's lives, thank you!